Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WWC2 antisense RNA 2 (WWC2-AS2) is a long non-coding RNA (lncRNA) gene, also referred to as C4orf38, FLJ30277, and other aliases, located on human chromosome 4[3]. It is classified as non-protein coding, with its transcript believed to function primarily at the RNA level rather than encoding a functional protein[3]. Specific biological function, disease associations, or mechanisms of action remain uncharacterized and are not well described in current literature. Unlike protein-encoding genes or well-defined therapeutic targets such as receptors, enzymes, or transporters, WWC2-AS2 has not been established as a therapeutic target, druggable molecule, or biomarker[3]. The gene is noted for its antisense relationship to the WWC2 gene, but direct experimental characterization of its regulatory effects or disease relevance is lacking. It belongs to the broader family of lncRNAs, which often regulate gene expression via antisense transcriptional interference or RNA interactions, but there are currently no reported drugs, biomarkers, or clinical safety concerns associated with WWC2-AS2[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WWC2 antisense RNA 2 (WWC2-AS2).